Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after Immunization | Zendy

Matthew D. Snape | Zendy; Dominic F. Kelly | Zendy; P. Salt | Zendy; Shawn J. Green | Zendy; Caroline Snowden | Zendy; Linda Diggle | Zendy; Astrid Borkowski | Zendy; LyMee Yu | Zendy; E. Richard Moxon | Zendy; A J Pollard | Zendy

Open Access

Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after Immunization

Author(s) -

Matthew D. Snape,

Dominic F. Kelly,

P. Salt,

Shawn J. Green,

Caroline Snowden,

Linda Diggle,

Astrid Borkowski,

LyMee Yu,

E. Richard Moxon,

A J Pollard

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/508776

Subject(s) - medicine , vaccination , meningococcal vaccine , immunization , neisseria meningitidis , titer , immunology , booster dose , meningococcal disease , antibody , immunity , immune system , biology , bacteria , genetics

The persistence of protection from meningococcal disease following immunization with serogroup C meningococcal (MenC) glycoconjugate vaccines in infancy is short-lived. The duration of protective immunity afforded by these vaccines in other at-risk age groups (i.e., adolescents and young adults) is not known. We evaluated the persistence of bactericidal antibodies following immunization with a MenC glycoconjugate vaccine (MenCV) in adolescents and the kinetics of immune response to a meningococcal AC plain polysaccharide vaccine (MenPS) challenge or a repeat dose of MenCV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research